The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

19 Sep 2014 07:00

RNS Number : 0810S
Amphion Innovations PLC
19 September 2014
 

Amphion Innovations plc

Interims Results for the 6 months to 30 June 2014

 

 

London and New York, 19 September 2014- Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces its unaudited interim results for the six months to 30 June 2014.

 

Highlights

 

· Generated revenue of US $240,000 during the period

 

· Net Asset Value per share at 30 June 2014 was US $0.04 (£0.024p)

 

· DataTern received favorable ruling from the Court of Appeals in relation to Microsoft case in NY

 

· Partner Company Axcess awarded US $40.5 million by jury which is now being appealed

 

· Partner Company Motif starts to explore opportunity for IPO

 

· Partner Company FireStar issued additional patents on key messaging technology

 

· Agreed a loan facility with an institutional lender for up to a maximum drawdown of US $10 million

 

Financial Results and Net Asset Value

 

Revenue for the six month period ended 30 June 2014 was US $240,000; approximately in line with the US $264,638 recorded in the first half of 2013. Revenue remained below prior periods mainly due to the absence of licensing income from DataTern while we await the ruling from the Federal Circuit Court of Appeals ("FCCA"). Regular operating costs of the business were lower than last year but total administrative expenses were higher due to fees paid to agents for fund-raising, combined with a further provision against amounts receivable from Partner Companies. As a result, the operating loss for the six months was US $1,769,275 compared with US $1,025,023 as reported in the same period of last year.

 

During the six month period the share price of Kromek plc fell from 75.5 pence to 46 pence and, as a result, the value of the company's holding of Kromek shares fell to US $9,796,364 from US $15,579,671. The Company's Net Asset Value at 30 June 2014 was US $0.04 (£0.02) compared to US $0.10 (£0.06) at the year end. Since the end of June, Kromek shares have staged a further recovery of approximately 10%

 

Amphion's holding of intellectual property assets is valued at amortised cost of US $507,642. The directors believe that the realizable value of the intellectual property assets held by DataTern is substantially in excess of the carrying value and the incremental investments being made in the pursuit of infringers of the IP will generate a significant profit. We believe that if we are successful in concluding licensing agreements, with the various infringing parties at levels that meet our expectations, the NAV per share would be significantly higher.

 

DataTern and the Intellectual Property Licensing Programme

 

As we reported in our Annual Report and Accounts 2013, in April 2014 DataTern received a ruling from the FCCA, which its legal advisors considered favorable. Following that ruling DataTern submitted a request to the FCCA for a reconsideration of certain aspects of the ruling, which were denied in July 2014 and so the ruling received in April is now final. As a result the case in New York has now been terminated, with the result that the previously unfavorable Markman ruling of August 2012 has, in the case of Microsoft, been nullified.

 

DataTern has recently filed its appeal in the MicroStrategy case with the FCCA. This was on hold, pending the resolution of the New York cases, but will now proceed and, if the court agrees to take the case, a hearing should be held by the end of the year and a ruling made by the end of the first quarter of 2015. There are 9 defendants in the MicroStrategy case. The cases in Texas which were on hold pending the Microsoft appeal, are now moving ahead again and we expect to have a Markman hearing in Texas within the next six months. There are 8 defendants in Texas.

 

Our legal team, supported by our extensive team of technical and patent experts, continues to believe in the strength of our intellectual property. Both of the two key patents have completed a comprehensive re-examination by the United States Patent and Trademark Office ("USPTO") and successfully emerged both fully validated and with additional claims added. It remains the firm and considered opinion of our team that the two patents are both valid and being infringed by a wide range of companies that are practicing this critical art. We believe that a Claim Construction ruling, which is fully reflective of our interpretation of the claims of the patents, would establish significant infringement by a large number of companies and we believe that we should be able to generate a significant amount of revenue from this asset over the next few years. Under the sharing agreement with DataTern, FireStar Software, where the technology and patents were originally developed, would share directly in this revenue stream.

 

Building Value in Our Partner Companies

 

Kromek completed its Initial Public Offering and was listed on the AIM market in October 2013. The company has recently announced final results for the fiscal year to 30 April 2014 which showed revenue up about 122% on the previous year. Amphion has a 10.6% shareholding of Kromek. The Annual Report for the last year can be found on the company website at www.kromek.com.

 

Motif has made further progress in developing its primary antibiotic programme and has been in discussion with two other groups with a view to license additional antibiotic technology into the company. The decision by the company to focus on its antibiotic programme is proving very timely given the growing recognition of the problem caused by resistance. In July, Prime Minister David Cameron announced the launch of a global taskforce established to coordinate an international effort to combat antibiotic resistant superbugs. Prime Minister Cameron commented, "If we fail to act, we are looking at an almost unthinkable scenario where antibiotics no longer work and we are cast back to the dark ages of medicine where treatable infections and injuries can kill once again". Motif's mission is to address this global health crisis by developing new antibiotics that work in different ways to those commonly used today. Given the high level of investor interest in this area that has recently emerged, we are now investigating the possibility of an IPO for Motif in the next few months.

 

In April the case Axcess brought against Baker & Botts LLP, the law firm, went to the jury which returned a verdict in favour of Axcess of US $40.5 million. This verdict was then overruled by the judge and Axcess is now in the process of pursuing an appeal to the Texas Court of Appeals which should be heard in the next six months. In parallel, we have worked closely with Axcess' legal advisors to evaluate the extent to which all 13 patents in its portfolio are being infringed. It is clear that many companies are now offering products or services that incorporate some of the basic wireless technology developed by the company over the last 15 years. A thorough review is still underway but it is already clear that a number of companies in the transportation and security sectors appear to be infringing one or more of these patents.

 

FireStar has recently been notified by the USPTO of the allowance of an additional patent relating to its innovative messaging technology. FireStar's technology is incorporated in its EdgeNode™ product and enables companies to facilitate low-cost, secure machine-to-machine messaging, in a novel architecture, which is well suited to the needs of the health care and financial industries.

 

WellGen has made further progress in the development of a novel functional beverage based on its patented anti-inflammatory ingredient. It has reached an agreement in principle to move forward with a US-based beverage company that has established distribution channels in the Mid-West of the US, with an opportunity to expand to other US markets and beyond.

 

Despite our cautious approach to valuation over the last two years, we continue to see a lot of opportunity to build and, in due course, extract value from each one of our Partner Companies, in addition to the IP licensing programme being pursued directly by DataTern.

 

Financing

 

In addition to continued support from the management team and board, we managed to conclude an agreement with an institutional lender on a loan facility, secured in part against the holding of Kromek shares. The company initially drew down US $2 million under the facility and has recently decided to draw an additional US $1 million under this facility in four monthly installments of US $250,000 starting in September. The loan can be repaid in cash, or Kromek shares, or the shares of Amphion in specified tranches over the twelve months following the draw down.

 

We have continued to cut costs wherever possible and the leadership team has continued to work with much reduced levels of current cash compensation. Our goal is to get through this challenging period in the market to the point where we can begin to realize the fruits of our investment in DataTern and our Partner Companies.

 

Prospects

 

While we remain cautious, the improvement in the public markets over the last two years has improved the prospects for financing and is a major development for Amphion. The return of a viable IPO market is a critical and positive development and, if it continues to improve, should have a positive effect on the availability of capital for Amphion and our Partner Companies. We believe there is significant inherent value to be developed and extracted from DataTern and our Partner Companies and we continue to be committed to the goal of generating and returning value to our shareholders from our current assets.

 

 

 

For further information please contact:

 

Amphion Innovations

Charlie Morgan

+1 212 210 6224

 

Novella Communications

Tim Robertson/ Ben Heath

+44 (0)20 3151 7008

 

Panmure Gordon Limited

Freddy Crossley/ Fred Walsh/ Duncan Montieth (Corporate Finance)

Charlie Leigh-Pemberton (Corporate Broking)

+44 (0)20 7866 2500

 

Amphion Innovations plc

Condensed consolidated statement of comprehensive income

For the six months ended 30 June 2014

Unaudited

Unaudited

Notes

Six months

Six months

Audited

ended

ended

Year ended

30 June 2014

30 June 2013

31 December 2013

Continuing operations

 US $

 US $

 US $

Revenue

4

240,000

264,638

1,016,990

Cost of sales

-

-

-

Gross profit

240,000

264,638

1,016,990

Administrative expenses

(2,009,275)

(1,289,661)

(3,593,735)

Operating loss

(1,769,275)

(1,025,023)

(2,576,745)

Fair value losses on investments

8

(5,783,308)

(2,379,958)

(3,363,558)

Interest income

419,467

288,783

856,564

Other gains and losses

(426,678)

639,294

(198,206)

Finance costs

(544,893)

(524,177)

(1,103,471)

Loss before tax

(8,104,687)

(3,001,081)

(6,385,416)

Tax on loss

6

(63)

(57,050)

3,222

Loss for the period

(8,104,750)

(3,058,131)

(6,382,194)

Other comprehensive income

Exchange differences arising on translation

of foreign operations

18

(53)

101

Other comprehensive income/(loss) for the period

18

(53)

101

Total comprehensive loss for the period

(8,104,732)

(3,058,184)

(6,382,093)

Loss per share

7

Basic

US

$ (0.06)

US

 $ (0.02)

US

 $ (0.04)

Diluted

US

$ (0.06)

US

 $ (0.02)

US

 $ (0.04)

 

 

 

Amphion Innovations plc

Condensed consolidated statement of financial position

At 30 June 2014

Unaudited

Unaudited

Audited

Notes

30 June 2014

30 June 2013

31 December 2013

US $

US $

US $

Non-current assets

Intangible assets

507,642

662,726

585,184

Property, plant, and equipment

805

308

Security deposit

13,600

13,600

13,600

Investments

8

30,104,315

36,596,983

35,746,087

30,625,557

37,274,114

36,345,179

Current assets

Prepaid expenses and other receivables

3,634,487

4,232,249

3,654,196

Cash and cash equivalents

1,147,354

22,643

353,964

4,781,841

4,254,892

4,008,160

Total assets

35,407,398

41,529,006

40,353,339

Current liabilities

Trade and other payables

9,191,443

8,486,383

9,411,563

Current portion of notes payable

10

8,308,600

6,308,600

Current portion of convertible promissory notes

10

8,758,250

9,543,671

17,500,043

17,244,633

25,263,834

Non-current liabilities

Convertible promissory notes

10

10,914,129

-

Notes payable

10

1,012,000

6,658,600

1,012,000

11,926,129

6,658,600

1,012,000

Total liabilities

29,426,172

23,903,233

26,275,834

Net assets

5,981,226

17,625,773

14,077,505

Equity

Share capital

11

2,693,319

2,682,757

2,693,319

Share premium account

36,042,868

36,009,331

36,042,868

Translation reserve

(13,550)

(13,396)

Retained earnings

(32,754,961)

(21,052,765)

(24,645,286)

Total equity

5,981,226

17,625,773

14,077,505

 

 

 

 

 

Amphion Innovations plc

Condensed consolidated statement of changes in equity

For the six months ended 30 June 2014

Unaudited

Foreign

Share

currency

Share

premium

translation

Retained

Notes

capital

account

reserve

earnings

Total

US $

US $

US $

US $

US $

Balance at 1 January 2013

 2,682,757

36,009,331

(13,497)

(18,100,060)

20,578,531

Loss for the period

-

-

-

(3,058,131)

(3,058,131)

Exchange differences arising on

translation of foreign operations

-

-

(53)

-

(53)

Total comprehensive loss for the period

-

-

(53)

(3,058,131)

(3,058,184)

Recognition of share-based payments

12

-

-

-

105,426

105,426

Balance at 30 June 2013

 2,682,757

36,009,331

(13,550)

(21,052,765)

17,625,773

Balance at 1 January 2014

 2,693,319

36,042,868

(13,396)

(24,645,286)

14,077,505

Loss for the period

-

-

-

(8,104,750)

(8,104,750)

Exchange differences arising on

translation of foreign operations

-

-

18

-

18

Total comprehensive loss for the period

-

-

18

(8,104,750)

(8,104,732)

Recognition of share-based payments

12

-

-

-

8,453

8,453

Dissolution of subsidiary

-

-

13,378

(13,378)

-

Balance at 30 June 2014

2,693,319

36,042,868

-

(32,754,961)

5,981,226

 

 

 

 

Amphion Innovations plc

Condensed consolidated statement of cash flows

For the six months ended 30 June 2014

Unaudited

Unaudited

Six months

Six months

Audited

ended

ended

Year ended

30 June 2014

30 June 2013

31 December 2013

US $

US $

US $

Operating activities

Operating loss

(1,769,275)

(1,025,023)

(2,576,745)

Adjustments for:

Depreciation of property, plant, and equipment

308

834

1,331

Amortisation of intangible assets

77,542

85,322

162,864

Recognition of share-based payments

8,453

105,426

(118,933)

(Increase)/decrease in prepaid & other receivables

19,709

(691,030)

(112,921)

Decrease in security deposit

-

57,135

57,135

Increase/(decrease) in trade & other payables

(220,118)

958,246

1,983,049

Interest expense

(544,893)

(524,177)

(1,103,471)

Other gains and losses

-

-

2,500

Income tax

(63)

(57,050)

3,222

Net cash used in operating activities

(2,428,337)

(1,090,317)

(1,701,969)

Investing activities

Interest received

419,467

288,783

856,564

Purchases of investments

(141,536)

(72,255)

(204,959)

Proceeds from sale of furniture

1,200

1,200

Adjustment to note payable for foreign exchange rate

328,293

(605,764)

179,657

Net cash from/(used in) investing activities

606,224

(388,036)

832,462

Financing activities

Proceeds on issue of promissory notes

2,000,000

450,000

1,012,000

Proceeds on issue of convertible promissory notes

1,042,165

-

Net cash from financing activities

3,042,165

450,000

1,012,000

Net increase/(decrease) in cash and cash equivalents

1,220,052

(1,028,353)

142,493

Cash and cash equivalents at the beginning of the period

353,964

413,276

413,276

Effect of foreign exchange rate changes

(426,662)

637,720

(201,805)

Cash and cash equivalents at the end of the period

1,147,354

22,643

353,964

 

Notes to the condensed consolidated financial statements (Unaudited)
 
For the six months ended 30 June 2014

1. General information

 

The condensed consolidated interim financial statements for the six months ended 30 June 2014 are unaudited and do not constitute statutory accounts within the meaning of the Isle of Man Companies Acts 1931 to 2004. The statutory accounts of Amphion Innovations plc for the year ended 31 December 2013 have been filed with the Registrar of Companies and contain an unqualified audit report which includes an emphasis of matter relating to significant uncertainty in respect of going concern and valuation of Partner Company investments. Copies are available on the company's website at www.amphionplc.com/reports.php.

 

2. Accounting policies

 

These condensed consolidated interim financial statements have been prepared in accordance with the recognition and measurement requirements of International Financial Reporting Standards (IFRS).

 

The accounting policies applied by the Group are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2013, except for the adoption of new standards and interpretations effective as of 1 January 2014.

 

The Group has adopted the following new standards and amendments to standards with a date of initial application of 1 January 2014.

· Amendments to IAS 27, Separate Financial Statements

· Amendments to IFRS 10, Consolidated Financial Statements

· Amendments to IAS 32, Financial Instruments: Presentation

· Amendments to IAS 36, Recoverable Amount Disclosures for Non-Financial Assets

 

Application of these standards and amendments had no significant impact on the Group's financial position or results of operations.

 

3. Use of judgements and estimates

 

In preparing these interim financial statements, management has made judgements, estimates, and assumptions that affect the reported amounts of assets, liabilities, contingencies, income, and expense. Actual results could differ from those estimated. Significant estimates in the Group's financial statements include the amounts recorded for the fair value of the financial instruments and other receivables. By their nature, these estimates and assumptions are subject to an inherent measurement of uncertainty.

 

Investments that are fair valued through profit or loss, as detailed in note 8, are all considered to be "Partner Companies". Those "Partner Companies" categorized as Level 3 are defined as investment in "Private Companies".

 

Fair value of financial instruments

 

The Directors use their judgement in selecting an appropriate valuation technique for financial instruments not quoted in an active market ("Private Investments"). The estimation of fair value of these Private Investments includes a number of assumptions which are not supported by observable market inputs. The carrying amount of the Private Investments is US $20 million.

 

Fair value of other receivables

 

Other receivables are stated at their amortised cost which approximates their fair value and are reduced by appropriate allowances for estimated irrecoverable amounts and do not carry any interest. The recovery of the advisory fees due at 30 June 2014 of US $1.4 million is dependent on a number of uncertain factors including the ability of the Partner Companies to raise finances (through current investors and new financing rounds) in order to support the future growth plans and therefore generate enough cash to be able to settle any outstanding debts.

 

 

 

 

4. Revenue

 

An analysis of the Group's revenue is as follows:

 

Six months ended

Six months ended

Year ended

30 June 2014

30 June 2013

31 December 2013

US $

US $

US $

Continuing operations

Advisory fees

240,000

264,638

939,490

License fees

-

-

77,500

240,000

264,638

1,016,990

 

A provision for doubtful accounts has been set up for US $240,000 for the advisory fees accrued from Partner Companies and US $240,000 of bad debt expense was recognized in the statement of comprehensive income.

 

As part of the agreement for DataTern, Inc. to purchase certain of the intangible assets in December 2007, a portion of future revenues from these patents will be retained by FireStar Software, Inc. No amounts have become payable to FireStar Software, Inc. to date. 

 

 

5. Segment information

 

For management purposes, the Group is currently organised into three business segments - advisory services, investing, and intellectual property. These business segments are the basis on which the Group reports its primary segment information.

 

Information regarding these segments is presented below.

 

Advisory

Investing

Intellectual

services

activities

property

Eliminations

Consolidated

Six months

 Six months

Six months

Six months

Six months

ended

ended

ended

ended

ended

30 June 2014

30 June 2014

30 June 2014

30 June 2014

30 June 2014

US $

US $

US $

US $

US $

REVENUE

External advisory fees

240,000

-

-

-

240,000

External license fees

-

-

-

-

-

Total revenue

240,000

-

-

-

240,000

Cost of sales

-

-

-

-

-

Gross profit

240,000

-

-

-

240,000

Administrative expenses

(593,770)

(1,019,364)

(396,141)

-

(2,009,275)

Segment result

(353,770)

(1,019,364)

(396,141)

-

(1,769,275)

Fair value losses on

investments

-

(5,783,308)

-

-

(5,783,308)

Interest income

-

419,467

-

-

419,467

Other gains and losses

(426,678)

-

-

(426,678)

Finance costs

-

(514,818)

(30,075)

-

(544,893)

Loss before tax

(353,770)

(7,324,701)

(426,216)

-

(8,104,687)

Income taxes

(63)

-

-

-

(63)

Loss after tax

(353,833)

(7,324,701)

(426,216)

-

(8,104,750)

 

Advisory

Investing

Intellectual

services

activities

property

Eliminations

Consolidated

Six months

 Six months

Six months

Six months

Six months

ended

ended

ended

ended

ended

30 June 2014

30 June 2014

30 June 2014

30 June 2014

30 June 2014

US $

US $

US $

US $

US $

OTHER INFORMATION

Segment assets

3,847,271

35,867,334

549,897

(4,857,104)

35,407,398

Segment liabilities

6,131,859

22,481,869

4,985,809

(4,173,365)

29,426,172

Depreciation

308

-

-

-

308

Amortisation

-

-

77,542

-

77,542

Recognition of share-based

payments

-

8,453

-

-

8,453

 

 

5. Segment information, (continued)

 

For management purposes for 30 June 2013, the Group was organised into three business segments - advisory services, investing activities, and intellectual property.

 

Advisory

Investing

Intellectual

services

activities

property

Eliminations

Consolidated

Six months

 Six months

Six months

Six months

Six months

ended

ended

ended

ended

ended

30 June 2013

30 June 2013

30 June 2013

30 June 2013

30 June 2013

US $

US $

US $

US $

US $

REVENUE

External advisory fees

264,638

-

-

-

264,638

External license fees

-

-

-

-

-

Total revenue

264,638

-

-

-

264,638

Cost of sales

-

-

-

-

-

Gross profit

264,638

-

-

-

264,638

Administrative expenses

(337,448)

(340,835)

(611,378)

-

(1,289,661)

Segment result

(72,810)

(340,835)

(611,378)

-

(1,025,023)

Fair value losses on

investments

-

(2,379,958)

-

-

(2,379,958)

Interest income

21,986

266,797

-

-

288,783

Other gains and losses

1,200

638,094

-

-

639,294

Finance costs

-

(519,365)

(4,812)

-

(524,177)

Profit/(loss) before tax

(49,624)

(2,335,267)

(616,190)

-

(3,001,081)

Income taxes

(57,000)

-

(50) 

-

(57,050)

Loss after tax

(106,624)

(2,335,267)

(616,240)

-

(3,058,131)

 

Advisory

Investing

Intellectual

services

activities

property

Eliminations

Consolidated

Six months

 Six months

Six months

Six months

Six months

ended

ended

ended

ended

ended

30 June 2013

30 June 2013

30 June 2013

30 June 2013

30 June 2013

US $

US $

US $

US $

US $

OTHER INFORMATION

Segment assets

4,094,132

41,763,222

705,141

(5,033,489)

41,529,006

Segment liabilities

5,936,699

18,224,036

4,092,246

(4,349,748)

23,903,233

Depreciation

387

-

447

-

834

Amortisation

-

-

85,322

-

85,322

Recognition of share-based

payments

-

105,426

-

-

105,426

 

 

 

5. Segment information, (continued)

 

Geographical segments

 

The Group's operations are located in the United States and the United Kingdom.

 

The following table provides an analysis of the Group's advisory fees by geographical location of the investment.

 

Advisory fees by

geographical location

Six months ended

Six months ended

30 June 2014

30 June 2013

US $

US $

United States

240,000

120,000

United Kingdom

-

144,638

240,000 

264,638

 

The following table provides an analysis of the Group's license fees by geographical location.

 

License fees by

geographical location

Six months ended

Six months ended

30 June 2014

30 June 2013

US $

US $

United States

-

-

Europe

-

-

-

-

 

 

The following is an analysis of the carrying amount of segment assets, and additions to fixtures, fittings, and equipment, analysed by the geographical area in which the assets are located:

 

Carrying amount

Additions to fixtures, fittings, and

of segment assets

equipment and intangible assets

Six months ended

Six months ended

Six months ended

Six months ended

30 June 2014

30 June 2013

30 June 2014

30 June 2013

US $

US $

US $

US $

United States

25,611,034

25,615,700

-

-

United Kingdom

9,796,364

15,913,306

-

-

35,407,398

41,529,006

-

-

 

 

 

 

 

 

 

 

6. Income tax expense

 

Six months ended

Six months ended

Year ended

30 June 2014

30 June 2013

31 December 2013

US $

US $

US $

Isle of Man income tax

-

-

-

Tax on US subsidiary

63

57,050

257

Tax on UK subsidiary

-

-

(3,479) 

Current tax / refund

63

57,050

(3,222)

 

From 6 April 2006, a standard rate of corporate income tax of 0% applies to Isle of Man companies, with exceptions taxable at the 10% rate, namely licensed banks in respect of deposit-taking business, companies that profit from land and property in the Isle of Man and companies that elect to pay tax at the 10% rate. No provision for Isle of Man taxation is therefore required. The Company is treated as a Partnership for U.S. federal and state income tax purposes and, accordingly, its income or loss is taxable directly to its partners.

 

The Company has four subsidiaries, two in the USA, one in the UK, and one in the Kingdom of Bahrain. The US subsidiaries, Amphion Innovations US Inc. and DataTern, Inc., are Corporations and therefore taxed directly. The US subsidiaries suffer US federal tax, state tax, and New York City tax on their taxable net income. The UK subsidiary, Amphion Innovations UK Limited, is liable to UK Corporation tax at rates up to 24% on its taxable profits and gains.

 

The Group charge for the period can be reconciled to the profit per the consolidated income statement as follows:

 

 US $

Loss before tax

(8,104,687)

Tax at the Isle of Man income tax rate of 0%

-

Effect of different tax rates of subsidiaries

operating in other jurisdictions

63

Current tax

63

  

 

7. Earnings per share

 

The calculation of the basic and diluted earnings per share attributable to the ordinary equity holders of the parent is based on the following data:

 

Earnings

Six months ended

Six months ended

 Year ended

30 June 2014

30 June 2013

31 December 2013

US $

US $

US $

Earnings for the purposes of basic and diluted earnings per share

(profit for the year attributable to equity holders of the parent)

(8,104,750)

(3,058,131)

(6,382,194)

Number of shares

Six months

Six months

ended

ended

Year ended

30 June 2014

30 June 2013

31 December 2013

Weighted average number of ordinary shares for

the purposes of basic earnings per share

146,884,071

146,220,250

146,285,723

Effect of dilutive potential ordinary shares:

Share options

-

-

-

Convertible promissory notes

63,806,662

31,990,100

31,990,100

Weighted average number of ordinary shares for

the purposes of diluted earnings per share

210,690,733

178,210,350

178,275,823

 

Share options that could potentially dilute basic earnings per share in the future have not been included in the calculation of dilute earnings per share because they are antidilutive.8. Investments

 

At fair value through profit or loss

 

Group

Level 1

Level 2

Level 3

Total

US $

US $

US $

US $

At 1 January 2014

15,579,671

-

20,166,416

35,746,087

Investments during the year

141,536

141,536

Transfers between levels

-

-

-

Fair value losses

(5,783,308)

-

-

(5,783,308)

At 30 June 2014

9,796,363

-

20,307,952

30,104,315

At 1 January 2013

3,225,783

35,678,903

38,904,686

Investments during the year

204,959

204,959

Transfers between levels

17,007,373

(3,225,783)

 (13,781,590)

Fair value losses

(1,427,702)

-

(1,935,856)

(3,363,558)

At 31 December 2013

15,579,671

-

20,166,416

35,746,087

 

The Company is required to classify fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. In the case of the Company, investments classified as Level 1 have been valued based on a quoted price in an active market. Investments classified as Level 2 have been valued using inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices). Fair values of unquoted investments classified as Level 3 in the fair value hierarchy have been determined in part or in full by valuation techniques that are not supported by observable market prices or rates. Investment valuations for Level 3 investments have been arrived at using a variety of valuation techniques and assumptions. For instance where the fair values are based upon the most recent market transaction but which occurred more than twelve months previously, the investments are classified as Level 3 in the fair value hierarchy.

 

The net decrease in fair value for the six months ended 30 June 2014 of US $5,783,308 is from the change in value of the public company and is based on a quoted price in an active market.

 

There were no transfers between levels in 2013.

 

Fair value determination

 

The Directors have valued the investments in accordance with the guidance laid down in the International Private Equity and Venture Capital Valuation Guidelines. The inputs used to derive the investment valuations are based on estimates and judgements made by management which are subject to inherent uncertainty. As such the carrying value in the financial statements at 30 June 2014 may differ materially from the amount that could be realized in an orderly transaction between willing market participants on the reporting date.

 

In making their assessment of fair value at 30 June 2014, management has considered the total exposure to each entity including equity, warrants, options, promissory notes, and receivables.

 

 

 

8. Investments, (continued)

 

Further information in relation to the directly held private investment portfolio at 30 June 2014 is set out below:

 

Fair value

Methodology

Unobservable inputs

US $

Private investments

20,307,952

Multiple methods used in combination including: Discount to last market price,

Discount (30%-100%),

discount to last financing round, price of future financing round, and third party

Price of fund raising.

valuation.

 

Given the range of techniques and inputs used in the valuation process and the fact that in most cases more than one approach is used, a sensitivity analysis is not considered to be a practical or meaningful disclosure. Shareholders should note however that increases or decreases in any of the inputs listed above in isolation may result in higher or lower fair value measurements.

 

9. Other financial assets and liabilities

 

The carrying amounts of the Group's financial assets and financial liabilities at the statement of financial position date are as follows.

 

30 June 2014

31 December 2013

Carrying

Fair

Carrying

Fair

amount

value

amount

value

US $

US $

US $

US $

Financial assets

Fair value through profit or loss

Fixed asset investments - designated

as such upon initial recognition

30,104,315

30,104,315

35,746,087

35,746,087

Currents assets

Loans and receivables

Security deposit

13,600

13,600

13,600

13,600

Prepaid expenses and other

receivables

3,634,487

3,634,487

3,654,196

3,654,196

Cash and cash equivalents

1,147,354

1,147,354

353,964

353,964

Financial liabilities

Amortised cost

Trade and other payables

9,191,443

9,191,443

9,411,563

9,411,563

Current portion of notes payable

8,308,600

8,308,600

6,308,600

6,308,600

Current portion of convertible promissory notes

-

-

9,543,671

9,543,671

Convertible promissory notes

10,914,129

10,914,129

-

-

Notes payable

1,012,000

1,012,000

1,012,000

1,012,000

 

The carrying value of cash and cash equivalents, the security deposit, prepaid expenses and other receivables, and trade and other payables, in the Directors' opinion, approximate to their fair value at 30 June 2014 and 31 December 2013. 

 

9. Other financial assets and liabilities, (continued)

 

The following table sets out the fair values of financial instruments not measured at fair value and analyses it by the level in the fair value hierarchy into which each fair value measurement is categorized at 30 June 2014.

Level 1

Level 2

Level 3

Total

US $

US $

US $

US $

Financial assets

Security deposit

-

13,600

-

13,600

Prepaid expenses and

other receivables

-

3,634,487

-

3,634,487

Cash and cash equivalents

-

1,147,354

-

1,147,354

-

 4,795,441

-

4,795,441

Financial liabilities

Trade and other payables

-

9,191,443

-

9,191,443

Current portion of notes payable

-

8,308,600

-

8,308,600

Convertible promissory notes

-

10,914,129

10,914,129

Notes payable

-

1,012,000

-

1,012,000

-

29,426,172

-

29,426,172

 

  

 

10. Promissory notes

 

Convertible promissory notes

 

The convertible promissory notes were to mature on 31 December 2013 but the due date was extended to 31 January 2014 by a meeting of the Noteholders on 6 December 2013. At a meeting of the Noteholders on 24 January 2014, it was agreed to extend the convertible promissory notes to 31 December 2015 on revised terms. The new notes can be convertible into ordinary shares of the Company at a conversion price of 10 pence and will pay interest of 7% if paid in ordinary shares or 5% if paid in cash or additional notes on a quarterly basis. Prior to maturity, the notes will be automatically converted into ordinary shares of the Company at the time that the closing price of the ordinary shares is equal or greater than 15 pence for 25 trading days. The Company is obliged to use 50% of its cash balances over £2 million (excluding any cash raised through any fund raising) to repay the notes. If, on or before 15 December 2014, the notes have not been converted or repaid in cash, the Noteholder will have the right to exchange part or the whole note into Kromek Group PLC ("Kromek") shares. The exchange rights will be exercisable from 15 December 2014 to 30 December 2014. In the event that the notes are not converted, repaid in cash, or exchanged for Kromek shares by 31 December 2015, the notes will be repaid by transferring Kromek shares held by the Company on the date of repayment to the Noteholders. For every £1 note, two warrants were issued. The warrants have an exercise price of 12 pence per share with an expiration date of 31 December 2015 or within 30 days of the early repayment of the note. In the event that the cash balances of the Company immediately following any repayment of the notes exceed £7 million, an amount equal to 20% of the surplus over £7 million but not exceeding 20% of the original principal amount of the notes will be paid to the Noteholders in proportion to the amounts of notes held by them at the time of repayment.

 

In April 2014, US $1,064,698 (£622,448) additional convertible promissory notes were issued in payment of the accrued interest payable on the notes as of 31 December 2013 and the quarter ended 31 March 2014. At 30 June 2014, the convertible promissory notes totaled US $10,914,129 and the warrants issued totaled 12,761,337.

 

The net proceeds received from the issue of the convertible promissory notes are classified as a financial liability due to the fact that the notes are denominated in a currency other than the Company's functional currency and that on any future conversion a fixed number of shares would be delivered in exchange for a variable amount of cash.

10. Promissory notes, (continued)

 

Promissory notes

 

In June 2014, the Company was granted a loan facility by an institutional lender (the "Lender"). The Company has drawn down an initial sum of US $2 million with a further draw down facility of up to a maximum of US $10 million, subject to the consent of each party. The facility is secured by part of Amphion's holding in Kromek Group plc ("Kromek") and may be repaid at the Company's discretion in cash, the issue of Amphion shares, or the payment of Kromek shares where the Lender will be subject to certain limitations including adherence to any existing lock-in and an orderly market agreement. Repayment will be on a monthly basis starting on 1 September 2014 with final payment due 1 June 2015. The interest rate of the loan is 12% per annum of the gross amount provided to the Company. As part of the loan terms the Lender received 8,532,350 3-year warrants in Amphion with an exercise price of 4.375 pence per share. In addition, Amphion will be issuing the Lender 663,627 3-year simulated warrants at an exercise price of 56.25 pence per share. If the Lender exercises the warrants, Amphion will pay the difference between the exercise price and the Kromek market price. The Company also paid a further 8% of the gross amount provided as an implementation fee. As part of the loan facility, the Directors agreed to a Deed of Postponement that regulates the Directors' rights in respect to the repayment of any debt due to them from the Company. The Directors agreed to defer payment of their debt by the Company until the loan facility is repaid in full. The funds are to be used for working capital for Amphion and its Partner Companies.

 

 

11. Share capital

 

30 June 2014

£

Authorised:

250,000,000 ordinary shares of 1p each

2,500,000

Number

£

US $

Balance as at 31 December 2013

146,884,071

1,468,840

2,693,319

Issued and fully paid:

Ordinary shares of 1p each

-

-

-

Balance as at 30 June 2014

146,884,071

1,468,840

2,693,319

 

12. Share based payments

 

In 2006 the Group established the 2006 Unapproved Share Option Plan ("the Plan") and it was adopted pursuant to a resolution passed on 8 June 2006. Under this plan, the Compensation Committee may grant share options to eligible employees, including Directors, to subscribe for ordinary shares of the Company. The number of Shares over which options may be granted under the Unapproved Plan cannot exceed ten percent of the ordinary share capital of the Company in issue on a fully diluted basis. The Plan will be administered by the Compensation Committee. The number of shares, terms, performance targets and exercise period will be determined by the Compensation Committee. During 2014, no options were issued under the Plan.

 

  

 

12. Share based payments, (continued)

 

2014

Weighted

average

Number of

exercise

share options

price (in £)

Outstanding at beginning of period

8,983,333

0.11

Granted during the period

-

-

Cancelled during the period

-

-

Expired during the period

-

-

Outstanding at the end of the period

8,983,333

0.11

Exercisable at the end of the period

8,941,668

0.11

 

Options are recorded at fair value on the date of grant using the Black-Scholes model. The Group recognized total costs of US $8,453 relating to equity-settled share-based payment transactions in 2014 which were expensed in the statement of comprehensive income during the period.

13. Related party transactions

 

Transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Details of transactions between the Group and other related partners are disclosed below.

 

During the period, the Group paid miscellaneous expenses for Motif BioSciences, Inc. ("Motif") such as office expenses. At 30 June 2014, the amount due from Motif is US $12,246.

 

A subsidiary of the Company has entered into an agreement with Axcess International, Inc. ("Axcess") to provide advisory services. Richard Morgan and Robert Bertoldi, Directors of the Company, are also Directors of Axcess. Amphion Innovations US Inc. will receive a monthly fee of US $10,000 pursuant to this agreement. The agreement is effective until 1 March 2015 and will renew on an annual basis until terminated by one of the parties. The monthly fee is suspended for any month in which Axcess' cash balance falls below US $500,000. Amphion Innovations US Inc. received no fee during the period ended 30 June 2014.

 

A subsidiary of the Company has entered into an agreement with Motif BioSciences, Inc. ("Motif") to provide advisory and consulting services. Richard Morgan, a Director of the Company, is also a Director of Motif. The annual fee for the services is US $240,000. The agreement is effective until 1 April 2015 and shall automatically renew for successive one year periods. Amphion Innovations US Inc.'s fee for the period ended 30 June 2014 was US $120,000. At 30 June 2014, US $840,000 of the advisory fees remain payable by Motif. The balance has been reduced by a provision for doubtful debts in the amount of US $360,000.

 

A subsidiary of the Company has entered into an agreement with m2m Imaging Corp. ("m2m") to provide advisory and consulting services. Robert Bertoldi, a Director of the Company, is also a Director of m2m. The quarterly fee under this agreement is US $45,000. This agreement renews on an annual basis until terminated by either party. Amphion Innovations US Inc.'s fee for the period ended 30 June 2014 was suspended. At 30 June 2014, US $630,000 of the advisory fees remain payable by m2m. This balance has been reduced by a provision for doubtful debts in the amount of US $600,000.

 

A subsidiary of the Company has entered into an agreement with WellGen, Inc. ("WellGen") to provide advisory and consulting services. Richard Morgan and Robert Bertoldi, Directors of the Company, are also Directors of WellGen. The fee under this agreement is US $60,000 per quarter. The agreement renews annually until terminated by either party. The subsidiary's fee for the period ended 30 June 2014 was US $120,000. At 30 June 2014, US $1,200,000

13. Related party transactions, (continued)

 

of the advisory fees remain payable. This balance has been reduced by a provision for doubtful debts in the amount of US $360,000.

 

A subsidiary of the Company has entered into an agreement with PrivateMarkets, Inc. ("PrivateMarkets") to provide advisory services. Richard Morgan, a Director of the Company, is also a Director of PrivateMarkets. The fee under this agreement is US $30,000 per quarter until the successful sale of at least US $3,000,000 and thereafter, US $45,000 per quarter. This agreement will renew annually unless terminated by either party. The subsidiary's fee for the period ended 30 June 2014 was suspended. At 30 June 2014, US $770,000 remains payable from PrivateMarkets. The payable has been reduced by a provision for doubtful debts in the amount of US $770,000.

 

Amphion Innovations US Inc. has entered into an agreement with DataTern, Inc. ("DataTern") (a wholly owned subsidiary of the Company) to provide advisory and consulting services. Richard Morgan and Robert Bertoldi, Directors of the Company, are also Directors of DataTern. The quarterly fee under this agreement is US $60,000 and renews annually unless terminated by either party. The subsidiary's fee for the period ended 30 June 2014 was suspended.

 

During 2013 Richard Morgan, a Director of the Company, advanced US $190,000 to a subsidiary of the Company under promissory notes. The promissory notes accrue interest at 5% per annum and are payable in three years. In 2010, Richard Morgan advanced US $352,866 to the Company. This advance is interest free and repayable on demand. At 30 June 2014, US $115,837 remains outstanding. The net amount payable by the Group at 30 June 2014 to Richard Morgan is US $2,196,060. The amount payable includes a voluntary salary reduction of US $1,515,766, US $341,779 of which will be payable at the discretion of the Board at a later date.

 

During 2010 through 2012, R. James Macaleer, the Chairman of the Company, advanced US $6,308,600 to the Company under promissory notes. The promissory notes accrue interest at 7% per annum and mature on 31 December 2014. In 2013, R. James Macaleer advanced US $600,000 to a subsidiary of the Company under a promissory note. The promissory note accrues interest at 5% per annum and is payable three years from issuance. As part of the terms of the loan facility the Company entered into in June 2014, the Directors agreed to a Deed of Postponement that defers payment of their promissory notes by the Company until the loan facility is repaid in full (note 10). At 30 June 2014, US $23,787 was due to Mr. Macaleer for Director's fees and US $1,148,564 was due for accrued interest on the promissory notes.

 

At 30 June 2014, US $117,537 was due to Gerard Moufflet, a Director of the Company, for Director's fees and US $8,337 for expenses.

 

At 30 June 2014, US $7,367 was due to Anthony Henfrey, a Director of the Company, for expenses. Dr. Henfrey waived his entitlement to receive his Director's fees for 2014.

 

At 30 June 2014, US $23,535 was due to Richard Mansell-Jones, a retired Director of the Company, for Director's fees.

 

At 30 June 2014, US $812,992 was due to Robert Bertoldi, a Director of the Company, for voluntary salary reductions of which US $188,769 is payable by the discretion of the Board at a later date.

 

14. Subsequent Events

 

In July and August 2014, the Company made advances of US $90,589 under a promissory note from Motif BioSciences, Inc.

 

In July and August 2014, the Company made advances of US $16,282 under a promissory note from PrivateMarkets Inc.

 

In July and August 2014, the Company made advances of US $40,000 under a promissory note from Axcess International Inc.

 

14. Subsequent Events, (continued)

 

On 1 July 2014, the Company issued £79,334 additional convertible promissory notes and 158,668 additional warrants in payment of the second quarter accrued interest expense on the convertible promissory notes.

 

On 8 July 2014, Amphion Innovations UK Ltd., a subsidiary of the Company, was dissolved.

 

In July 2014, the Company issued 690,663 ordinary shares to certain Directors in payment of their directors' fees for the fourth quarter of 2013 and the first two quarters of 2014 priced at 2.175 pence.

 

On 7 August 2014, Anthony W. Henfrey retired as Director of the Company.

 

In August 2014, the Company was re-registered as a company incorporated under the Companies Act 2006 (as amended).

 

In August 2014, the Company increased its authorized share capital to 500,000,000 ordinary shares from 250,000,000 ordinary shares.

 

In August 2014, Miroslaw Izienicki was appointed Non-executive Director to the Board of Amphion Innovations plc.

 

In August 2014, the Company signed a supplemental loan agreement deed with an institutional lender to make an additional US $1,000,000 draw down on the loan facility in four monthly advances of US $250,000 starting in September. Repayment will be on a monthly basis starting on 1 October 2014. (See note 10).

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR GMGMLNRFGDZM
Date   Source Headline
31st Dec 20191:15 pmRNSAmphion Innovations
31st Dec 201912:36 pmRNSCancellation of trading on AIM
20th Nov 20197:00 amRNSDirectors' Dealings and Business Update
18th Oct 20197:00 amRNSSettlement of loan facility
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
11th Oct 20197:00 amRNSSale of Partner Company Shares
3rd Oct 20197:00 amRNSSale of Partner Company Shares
25th Sep 20197:00 amRNSAmended Terms on Loan Facility
10th Sep 20194:56 pmRNSSale of Partner Company Shares
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
9th Aug 20194:14 pmRNSDirectorate Change
9th Aug 20193:51 pmRNSSale of Partner Company Shares
1st Jul 20197:30 amRNSSuspension - Amphion Innovations Plc
27th Jun 20193:00 pmRNSAnnual Report and Accounts Update
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20197:00 amRNSLoan facility update
31st May 201910:28 amRNSHolding(s) in Company
20th May 20196:14 pmRNSHolding(s) in Company
1st Apr 20194:40 pmRNSSecond Price Monitoring Extn
1st Apr 20194:35 pmRNSPrice Monitoring Extension
1st Apr 20197:00 amRNSUpdate on Loan Facility
20th Mar 20197:00 amRNSHolding(s) in Company
19th Mar 20192:33 pmRNSSale of Partner Company Shares
18th Mar 20192:00 pmRNSPrice Monitoring Extension
15th Mar 20197:01 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSSale of Partner Company Shares
11th Mar 20194:41 pmRNSAmended Terms on Loan Facility
26th Feb 20197:00 amRNSConvertible Promissory Note Extended
14th Feb 20198:00 amRNSStatement re. Motif Bio plc
7th Feb 20199:40 amRNSStmnt re Share Price Movement
1st Feb 20197:00 amRNSAppointment of Joint Broker
21st Jan 20197:00 amRNSWellGen Finalises License Agreement
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
16th Oct 20187:00 amRNSExtended Repayment and Draw Down on Loan Facility
28th Sep 20187:00 amRNSHalf-year Report
5th Sep 20187:00 amRNSBoard Change
23rd Aug 20183:20 pmRNSPolarean update
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
21st Aug 20187:00 amRNSSale of Partner Company Shares
1st Aug 20184:47 pmRNSResult of AGM
29th Jun 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSFinal Results
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
23rd May 20187:00 amRNSSale of Partner Company Shares
20th Apr 20187:00 amRNSDirectorate Change
29th Mar 20187:00 amRNSAIM Admission & First Day of Dealings
29th Mar 20187:00 amRNSUpdate on Polarean Imaging IPO
26th Mar 20187:31 amRNSUpdate on Polarean Imaging proposed AIM IPO
2nd Mar 20187:00 amRNSConvertible promissory note extended to December
10th Jan 20185:09 pmRNSDirector dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.